Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.

Siroy AE, Aung PP, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Milton DR, Curry JL, Ivan D, Prieto VG.

Hum Pathol. 2017 Jan;59:48-54. doi: 10.1016/j.humpath.2016.09.010. Epub 2016 Sep 22.

PMID:
27666765
2.

Lymph node metastases of melanoma: challenges for BRAF mutation detection.

Chen G, Dudley J, Tseng LH, Smith K, Gurda GT, Gocke CD, Eshleman JR, Lin MT.

Hum Pathol. 2015 Jan;46(1):113-9. doi: 10.1016/j.humpath.2014.09.014. Epub 2014 Oct 7.

PMID:
25456393
3.

BRAF mutation-positive folliculotropic metastatic melanoma.

Brick KE, Halling KC, Khan YK, Peters MS.

Am J Dermatopathol. 2013 Jul;35(5):609-12. doi: 10.1097/DAD.0b013e31827a0bfb.

PMID:
23715079
4.

Benign nodal nevi frequently harbor the activating V600E BRAF mutation.

Taube JM, Begum S, Shi C, Eshleman JR, Westra WH.

Am J Surg Pathol. 2009 Apr;33(4):568-71. doi: 10.1097/PAS.0b013e31818a64fb.

PMID:
19033861
5.

BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.

Yaman B, Kandiloğlu G, Akalin T.

Am J Dermatopathol. 2016 Feb;38(2):113-20. doi: 10.1097/DAD.0000000000000404.

PMID:
26630683
6.

Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.

Picard M, Pham Dang N, D'Incan M, Mansard S, Dechelotte P, Pereira B, Mondie JM, Barthelemy I.

Br J Dermatol. 2014 Jul;171(1):108-14. doi: 10.1111/bjd.12939. Epub 2014 Jul 7.

PMID:
24602025
7.

Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.

Jurkowska M, Gos A, Ptaszyński K, Michej W, Tysarowski A, Zub R, Siedlecki JA, Rutkowski P.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8487-93. eCollection 2015.

8.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, From L, Busam KJ, Hao H, Orlow I, Kanetsky PA, Luo L, Reiner AS, Paine S, Frank JS, Bramson JI, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Conway K; GEM Study Group.

JAMA Oncol. 2015 Jun;1(3):359-68. Erratum in: JAMA Oncol. 2015 Jun;1(3):285.

9.

BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.

Mudaliar K, Tetzlaff MT, Duvic M, Ciurea A, Hymes S, Milton DR, Tsai KY, Prieto VG, Torres-Cabala CA, Curry JL.

Hum Pathol. 2016 Apr;50:79-89. doi: 10.1016/j.humpath.2015.12.003. Epub 2015 Dec 18.

PMID:
26997441
10.

BRAF mutation screening in melanoma: is sentinel lymph node reliable?

Nardin C, Puzenat E, Prétet JL, Algros MP, Doussot A, Puyraveau M, Mougin C, Aubin F.

Melanoma Res. 2015 Aug;25(4):328-34. doi: 10.1097/CMR.0000000000000166.

PMID:
26020488
11.

BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.

O'Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron CCBB.

J Clin Pathol. 2017 Nov;70(11):935-940. doi: 10.1136/jclinpath-2017-204367. Epub 2017 Apr 19.

PMID:
28424234
12.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

PMID:
21343559
13.

Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.

Anwar MA, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E.

J Surg Res. 2016 Jun 15;203(2):407-15. doi: 10.1016/j.jss.2016.04.029. Epub 2016 Apr 23. Review.

PMID:
27363650
14.

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.

Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK.

Eur J Cancer. 2014 Oct;50(15):2668-76. doi: 10.1016/j.ejca.2014.06.009. Epub 2014 Jul 25.

PMID:
25070294
15.

BRAF V600E mutation-specific antibody: A review.

Ritterhouse LL, Barletta JA.

Semin Diagn Pathol. 2015 Sep;32(5):400-8. doi: 10.1053/j.semdp.2015.02.010. Epub 2015 Feb 7. Review.

PMID:
25744437
16.

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA.

Am J Surg Pathol. 2013 Jan;37(1):61-5. doi: 10.1097/PAS.0b013e31826485c0.

PMID:
23026937
17.

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.

Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA.

Br J Cancer. 2016 Mar 29;114(7):801-8. doi: 10.1038/bjc.2016.44. Epub 2016 Feb 25.

18.

A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.

Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW.

Asia Pac J Clin Oncol. 2016 Dec;12(4):403-408. doi: 10.1111/ajco.12574. Epub 2016 Aug 4.

PMID:
27488807
19.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.

JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.

PMID:
26181250
20.

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA.

Cancer. 2017 Apr 15;123(8):1372-1381. doi: 10.1002/cncr.30463. Epub 2016 Dec 2.

Supplemental Content

Support Center